MACH7 TECHNOLOGIES LIMITED — Investor Presentation 2019

Apr 1, 2019

Investor Presentation, April 2019

Disclaimer ‘Forward-Looking' Statements

Summary of information: This presentation contains general and background information about Mach7 Technologies Limited (“ M7T ”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in M7T nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by M7T and all other documents provided to you by M7T. The information in this presentation remains subject to change without notice. M7T is not responsible for providing updated information and assumes no responsibility to do so.

Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire M7T securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities or and other financial products. Cooling off rights do not apply to the acquisition of M7T securities. M7T assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

Disclaimer: M7T and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of M7T.

Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of M7T. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

Risks: An investment in M7T securities is subject to investment and other known and unknown risks, some of which are beyond the control of M7T. You should have regard to the ‘Key Risks’ section of this presentation which outlines some of these risks.

Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in M7T or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in M7T will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of M7T.

No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by M7T have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”) and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons.

Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD$). The information in this presentation remains subject to change without notice.

Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) (“Corporation Act”)) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.

No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.

==> picture [189 x 69] intentionally omitted <==

==> picture [80 x 24] intentionally omitted <==

2

Who is Mach7 (ASX:M7T)?

• Enterprise Imaging Software provider to hospitals and clinics

• Global imaging market >US$3BN

• Delivery: On-premise, cloud solutions

• Growing global customer base: USA, UK, Qatar, South East Asia …

• Two revenue models: SaaS & capital sales

• Employing ~40 staff

==> picture [189 x 69] intentionally omitted <==

==> picture [480 x 223] intentionally omitted <==

----- Start of picture text -----

USA HQ
Burlington,
VT
ASEAN
Operations
Singapore
Group HQ
Melbourne
----- End of picture text -----

3

Mach7 Technologies (M7T:AX)

FINANCIAL INFORMATION ($A)

MAJOR SHAREHOLDERS

Share price $0.185 Number of shares (m) 147.8m Market Capitalisation $27.3m Cash (31-Dec-18) $3.2m Debt (31-Dec-18) $0.5m Enterprise Value $24.8m

JM Financial Group 13.8% BV Healthcare 7.9% Oceania Capital 6.3% Ravi Krishnan (founder) 3.8%

==> picture [189 x 69] intentionally omitted <==

==> picture [80 x 24] intentionally omitted <==

Mach7 Evolution – Company & Product

==> picture [72 x 66] intentionally omitted <==

==> picture [51 x 50] intentionally omitted <==

==> picture [898 x 31] intentionally omitted <==

2007 2010 2012 2016 2017 Mach7 First Pilots First Listed M7T:ASX Expanded Product Founded Deployed Commercial Offerings Wins Specialty Applications: v8 Enterprise Imaging Platform: v11 Data Services Platform: v12 Vendor Neutral Archive Management Studio Clinical Studio Diagnostic Studio

==> picture [189 x 69] intentionally omitted <==

==> picture [80 x 24] intentionally omitted <==

5

What is Enterprise Imaging

Drivers of Enterprise Imaging

Enterprise imaging

Electronic Health Record (EHR) as a precursor to Enterprise Imaging Hospital Consolidation Simplify Supply Chains Sharing, outsourcing & Need for scalable caseload balancing storage

==> picture [189 x 69] intentionally omitted <==

• Mach7’s Management Studio underpins our Enterprise Imaging product

• Recent Enterprise Imaging customer wins – HAHK ($15M)

==> picture [80 x 24] intentionally omitted <==

Diagram from Signify Research *Signify Research, USD

6

Mach7 Enterprise Imaging Product Strategy

==> picture [260 x 186] intentionally omitted <==

• Vendor Neutral Archive (VNA) is the cornerstone of the EI market

• Mach7 is considered a pioneer in the VNA market space

==> picture [267 x 238] intentionally omitted <==

----- Start of picture text -----

Referring
Physician Radiologist
----- End of picture text -----

• Core Capability is providing Enterprise Imaging (EI) solutions for healthcare

==> picture [339 x 220] intentionally omitted <==

• Mach7 sells a Picture Archive and Communications System (PACS) with its partner Client Outlook

• Enterprise-first strategy (vs. Radiology-first)

==> picture [189 x 69] intentionally omitted <==

==> picture [80 x 24] intentionally omitted <==

7

Addressable Global Imaging Market

Mach7 Addressable Market*

3,500
500 1,000 1,500 2,000 2,500 3,000
-
	2016		2017		2018		2019			2020		2021		2022
					PACS		EI	VNA	&	IE

==> picture [189 x 69] intentionally omitted <==

*Market Data from Signify Research

• Enterprise Imaging Market (EI) $520M 2018 – with forecast growth ~30% p/a for next two years**

• EI market is fastest growing market

• Standalone departmental PACS $2BN 2018* however market is shrinking in favour of Enterprise Imaging

==> picture [80 x 24] intentionally omitted <==

8

Global VNA Market Share, 2017

==> picture [736 x 434] intentionally omitted <==

----- Start of picture text -----

Other, 13%
IBM Watson
Health , 22%
Sectra AB , 3%
Mach7 , 3%
Agfa Healthcare
, 4%
Carestream , 4%
GE Healthcare ,
Hitachi , 7%
17%
Hyland
Healthcare , 7%
NTT , 8% Fujifilm Medical
Market Data from Signify Research , 11%
9
----- End of picture text -----*

==> picture [80 x 24] intentionally omitted <==

“Mach7 Management Studio” - VNA

Why customers buy a VNA:

==> picture [122 x 65] intentionally omitted <==

----- Start of picture text -----

Mach7’s Core
Product is VNA
“Management
Studio”
----- End of picture text -----

• 55 Active $$ Customers

==> picture [189 x 69] intentionally omitted <==

• Providing additional storage

• Long-term disaster recovery

• Connecting disparate PACS across hospital

• Today: VNA is purchased as a precursor to Enterprise Imaging

Many healthcare providers are moving toward a multiclinical Management Platform for all content across their hospital or enterprise.

==> picture [80 x 24] intentionally omitted <==

10

“Mach7 Diagnostic Studio” - PACS Solution

==> picture [541 x 304] intentionally omitted <==

==> picture [199 x 64] intentionally omitted <==

• An integration platform first →enables speed, performance, flexibility

• True zero-footprint (ZFP) viewer → NO client-side software

• One ZFP platform for allusers and devices; browser and device agnostic

• Does NOT have 100% streaming like all other solutions – 100% diagnostic 100% of the time – streaming

• viewers are not capable of this

• Works in a virtual machine environment; leverages existing infrastructure, does not require specialized hardware

• Highly scalable; can support 1000’s of unique users on one VM

Recent enterprise PACS wins – Sentara healthcare

==> picture [80 x 24] intentionally omitted <==

*Market Data from Signify Research 11

Mach7 Competitive Advantages

==> picture [749 x 399] intentionally omitted <==

----- Start of picture text -----

Interoperability across the
enterprise (connecting all
systems, across all ‘ologies’)
Customer
controls their Attractive
own data – Price Point
easy
user interface and
rules engine
Very Little Hardware
(Lowers cost and Ease of Install
accelerates install)
----- End of picture text -----

==> picture [189 x 69] intentionally omitted <==

==> picture [80 x 24] intentionally omitted <==

12

Recent Wins – This Quarter (Q3 FY19)

==> picture [699 x 401] intentionally omitted <==

----- Start of picture text -----

$2.1M / 5
yrs.
$365k / 5
yrs.
$57k
$43k
$25k
Mississippi State Maine Health Loyola Sampson Sentara
University (Cardiology University Regional Healthcare
Veterinary viewer Health System Medical Centre (Diagnostic
(Clinical Portal) integration) (Migration) (VNA) Studio)
----- End of picture text -----*

==> picture [189 x 69] intentionally omitted <==

==> picture [80 x 24] intentionally omitted <==

*New Customers

13

Hospital Authority of Hong Kong

==> picture [138 x 59] intentionally omitted <==

• Deal value HK$81 Million (~ A$15M) / 5 years

==> picture [397 x 236] intentionally omitted <==

• Enterprise Imaging and Viewer for entire Hong Kong territory

• The Hospital Authority manages 43 public hospitals and institutions, 48 specialist outpatient clinics and 73 general outpatient clinics.

• Customer Objective:

• Reduce complexities and costs related to system integration and the consolidation, sharing, access and management of medical imaging data across Hong Kong.

==> picture [189 x 69] intentionally omitted <==

==> picture [80 x 24] intentionally omitted <==

Sentara Healthcare

==> picture [334 x 214] intentionally omitted <==

• Leading hospital system in Virginia & NC, USA

• 12 hospitals, 1000 + Physicians, 3800 provider staff

• 8 PACS systems (GE, Agfa, Fuji, Medstream Cardiology)

==> picture [189 x 69] intentionally omitted <==

==> picture [94 x 53] intentionally omitted <==

• Enterprise Imaging, Migration & PACS Modernisation Projects

• Mach7 VNA and 20 million study migration underway.

• Recent PACS modernization contract won $2.1M over 5 years + volume expansion. 100% GM.

• Customer Objectives

• Reduce complexities and costs related to system integration and the consolidation, sharing, access and management of medical imaging data across all ‘ologies’

• Common PACS platform across all facilities with a single Database and Archive

• Sentara’s objectives included the following”

  • Innovative Technology

  • Cost Reduction

  • Workflow Efficiency

  • Geographic Freedom

==> picture [80 x 24] intentionally omitted <==

Mach7 Customer Examples

==> picture [170 x 30] intentionally omitted <==

• Academic medical center

• Enterprise Imaging Platform

• • Client since 2014

==> picture [104 x 38] intentionally omitted <==

• Academic medical center, 130 sites

• • Communications Workflow Engine

• • Client since 2012

==> picture [189 x 69] intentionally omitted <==

----- Start of picture text -----

•
----- End of picture text -----

==> picture [147 x 30] intentionally omitted <==

==> picture [81 x 37] intentionally omitted <==

• Partners Healthcare System

• • Academic medical centers

• • Client since 2010

==> picture [181 x 50] intentionally omitted <==

• 1 of 10 largest US hospital systems

• • 30+ hospitals & clinics

• • Client since 2015

==> picture [167 x 49] intentionally omitted <==

• Academic medical center serving the State of Vermont

• Client since 2017

==> picture [94 x 53] intentionally omitted <==

• Hospital system serving VA & NC

• • 12+ hospitals &

• clinics

• Client since 2014

==> picture [80 x 24] intentionally omitted <==

16

Mach7 Customer Examples

==> picture [152 x 36] intentionally omitted <==

• Qatar’s leading hospital system

• 12 + hospitals

• Client since 2009

==> picture [154 x 24] intentionally omitted <==

• Statewide healthcare provider system

• 30+ hospitals and clinics

==> picture [173 x 37] intentionally omitted <==

• 443-bed acute care hospital

• Enterprise Imaging Platform

• Client since 2018

• Client since 2016

==> picture [77 x 25] intentionally omitted <==

• US & UK provider

• Communication Workflow Engine & Image sharing

• Client since 2013

==> picture [189 x 69] intentionally omitted <==

==> picture [115 x 52] intentionally omitted <==

• Radiology service provider

• Enterprise Imaging Platform

• Client since 2014

==> picture [133 x 23] intentionally omitted <==

• 11 hospital health system in greater NYC

• Enterprise Imaging Platform

• Client since 2010

==> picture [80 x 24] intentionally omitted <==

17

Revenue Models

	Capital Sales	Capital Sales	Subscription Sales	Subscription Sales
Revenue Component	Priced	Revenue Recognised	Priced	Revenue Recognised
Software license fees	By Procedure Volume	Upfront when license is provided	By Procedure Volume	Monthly*
Annual support	% of License	Monthly*	By Procedure Volume	Monthly*
Professional Services	By Labour Hours	As services are delivered (implementation, training)	By Labour Hours	As services are delivered (implementation, training)

Two revenue models – customers are offered a choice – either Capital or Subscription (SaaS) Vast majority of Mach7’s customers are Capital Sales (at their choice) *Recurring revenues

==> picture [189 x 69] intentionally omitted <==

==> picture [80 x 24] intentionally omitted <==

18

Revenues

Annual Recurring Revenue (ARR) A$

8,000,000 7,000,000 6,000,000 5,000,000 4,000,000 3,000,000 2,000,000 1,000,000 0 2016 2017 2018 2019* Recognised AR + Sub CARR

• Total Contracted ARR 50% growth (today v ’18)

• Yearly ARR 30% growth (FY19 est. vs ‘18)

• On track to exceed FY2018 total revenue of $8.6M with existing contracts

• Q4 contracts will add additional revenues

*FY19 ARR is an estimate

==> picture [80 x 24] intentionally omitted <==

19

Growth Strategy

Focus on core products: enterprise imaging market space

==> picture [514 x 343] intentionally omitted <==

Focus on allocating resources towards commercial side of the business: sales, marketing, product management

Focus on major markets where we already have an install base and good brand recognition: USA, Asia, Qatar, Saudi Arabia

==> picture [189 x 69] intentionally omitted <==

==> picture [80 x 24] intentionally omitted <==

20

What’s next? Next six months…

==> picture [426 x 285] intentionally omitted <==

 Continued progress to cashflow break-even for 12 months ending March 2020  Revenue growth FY 2019 vs 2018

• Contract wins

 Re-investing some cost savings into commercial roles

==> picture [189 x 69] intentionally omitted <==

==> picture [80 x 24] intentionally omitted <==

21

Mach7 Board and Leadership Team

==> picture [95 x 95] intentionally omitted <==

Damien Lim NON-EXECUTIVE CHAIRMAN

• 21+ years experience in private equity and investment banking

• Co-founder of BioVeda Capital

• Currently serves on a number of boards and advisory committees

==> picture [95 x 87] intentionally omitted <==

David Chambers NON-EXECUTIVE DIRECTOR

• 30+ years’ extensive experience in HCIT and Life Science industry.

• Former CEO of Promedicus & Visage Imaging

• Currently Managing Director, Asia-Pacific, of Allscripts Healthcare Solutions

==> picture [189 x 69] intentionally omitted <==

==> picture [87 x 87] intentionally omitted <==

Eliot Siegel, MD NON-EXECUTIVE DIRECTOR

• Thought leader in the world of radiology and imaging informatics. Professor and Vice Chair at the University of Maryland School of Medicine

• Chief of Radiology & Nuc Med for the Veterans Affairs Maryland Healthcare System

==> picture [91 x 91] intentionally omitted <==

Wayne Spittle NONEXECUTIVE DIRECTOR

• Extensive industry experience in the global healthcare

• Currently: consultant at Samsung Medison; Advisor at Novum Waves

• Former Executive VP with Samsung Medison and Health and Medical Equipment division

==> picture [64 x 94] intentionally omitted <==

==> picture [83 x 84] intentionally omitted <==

==> picture [70 x 32] intentionally omitted <==

----- Start of picture text -----

Jenni Pilcher
CFO, Company
Secretary
----- End of picture text -----

==> picture [45 x 33] intentionally omitted <==

----- Start of picture text -----

Mike
Lampron
CEO
----- End of picture text -----

• Executive experience in ASXlisted healthcare companies

• 20+ years experience in business and operational management for HCIT companies

• Former CFO of Alchemia, and CFO and Co-Sec of Mesoblast (ASX:MSB)

• Mike is responsible for our customers’ success while driving excellence throughout

• Part of global finance teams at Cadbury Schweppes and Medeva , PLC

==> picture [141 x 92] intentionally omitted <==

----- Start of picture text -----

Ravi
Krishnan
FOUNDER,
CSO
----- End of picture text -----

• Founding partner of Mach7 Technologies

• Nearly 20 years of experience with technology intricacies that drive medical imaging

• Previously worked at GE Healthcare and Agfa Healthcare

==> picture [80 x 24] intentionally omitted <==

22